iBio, Inc. (IBIO) - צמיחת רווחים בשנה הנוכחית

iBio, Inc. (IBIO) is betting on AI-driven antibody development to combat cancer, and GURU.Markets quotes form this chart, where the annual earnings per share growth indicator reaches -6.20 as the final level mark. However, iBio, Inc. (IBIO) faces a rapid cash burn and pipeline uncertainty. Meanwhile, the active recruitment of AI biologists and stock option programs allow the company to retain its valuable scientific staff.

This metric is calculated as the percentage deviation of current earnings per share from the value of the same period last year. This metric measures net income dynamics, determining the efficiency of business capitalization. For iBio, Inc. (IBIO), which is burning reserves on AI platforms, EPS growth is hindered by constant share issuance. Analysis based on the annual EPS change scale allows for an assessment of the rate of shareholder dilution.